Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02)

Ji Yun Lee, Jong Mu Sun, Dong Ryul Oh, Sung Hee Lim, Juna Goo, Se Hoon Lee, Sung Bae Kim, Keon Uk Park, Hoon Kyo Kim, Dae Sik Hong, Jun Suk Kim, Seong Geun Kim, Seong Yoon Yi, Hwan Jung Yun, Myung Soo Hyun, Hyo Jung Kim, Sin Ho Jung, Keunchil Park, Yong Chan Ahn, Myung Ju Ahn

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose Triweekly delivery of cisplatin concurrent with a course of radiation therapy (RT) has been the standard regimen for treatment of locally advanced nasopharyngeal carcinoma (NPC) despite a high level of concern regarding treatment-related complications. We conducted a randomized phase II study to compare weekly and triweekly cisplatin delivery during RT with respect to efficacy and toxicity profiles. Material and methods Patients with locally advanced NPC (stage II-IVb) were randomly assigned to a regimen of either seven doses of cisplatin (40 mg/m2) given once a week or three doses of cisplatin (100 mg/m2) given every 3 weeks concurrently during RT. Results Of 109 eligible patients, 53 were assigned to the weekly regimen and 56 to the triweekly regimen. The two groups were comparable with respect to demographic and clinical characteristics. There were no significant differences in mean RT dose (68.3 Gy vs. 67.3 Gy, p = 0.559) and mean cisplatin dose (248.9 mg/m2 vs. 256.6 mg/m2, p = 0.433) between the two regimens. The primary endpoint was 3-year progression-free survival, which was not different between the regimens (64.9% vs. 63.8%, p = 0.074). Overall, the occurrence of grade 3-4 toxicities was similar between the two arms (47.2% vs. 39.3%, p = 0.443). Quality of life (QoL) related to functional outcomes 3 weeks after treatment completion was better for the weekly regimen. Conclusions Although no definitive conclusions can be made, a once-weekly cisplatin regimen appears to be associated with improved QoL and is not inferior to the standard triweekly regimen with respect to efficacy and toxicity profiles.

Original languageEnglish
Pages (from-to)244-250
Number of pages7
JournalRadiotherapy and Oncology
Volume118
Issue number2
DOIs
Publication statusPublished - 2016 Feb 1

Fingerprint

Nasopharyngeal Neoplasms
Cisplatin
Radiotherapy
Quality of Life
Disease-Free Survival
Therapeutics
Demography

Keywords

  • Concurrent chemoradiation therapy
  • Efficacy
  • Nasopharyngeal cancer
  • Quality of life
  • Toxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer : A multicenter randomized phase II trial (KCSG-HN10-02). / Lee, Ji Yun; Sun, Jong Mu; Oh, Dong Ryul; Lim, Sung Hee; Goo, Juna; Lee, Se Hoon; Kim, Sung Bae; Park, Keon Uk; Kim, Hoon Kyo; Hong, Dae Sik; Kim, Jun Suk; Kim, Seong Geun; Yi, Seong Yoon; Yun, Hwan Jung; Hyun, Myung Soo; Kim, Hyo Jung; Jung, Sin Ho; Park, Keunchil; Ahn, Yong Chan; Ahn, Myung Ju.

In: Radiotherapy and Oncology, Vol. 118, No. 2, 01.02.2016, p. 244-250.

Research output: Contribution to journalArticle

Lee, JY, Sun, JM, Oh, DR, Lim, SH, Goo, J, Lee, SH, Kim, SB, Park, KU, Kim, HK, Hong, DS, Kim, JS, Kim, SG, Yi, SY, Yun, HJ, Hyun, MS, Kim, HJ, Jung, SH, Park, K, Ahn, YC & Ahn, MJ 2016, 'Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02)', Radiotherapy and Oncology, vol. 118, no. 2, pp. 244-250. https://doi.org/10.1016/j.radonc.2015.11.030
Lee, Ji Yun ; Sun, Jong Mu ; Oh, Dong Ryul ; Lim, Sung Hee ; Goo, Juna ; Lee, Se Hoon ; Kim, Sung Bae ; Park, Keon Uk ; Kim, Hoon Kyo ; Hong, Dae Sik ; Kim, Jun Suk ; Kim, Seong Geun ; Yi, Seong Yoon ; Yun, Hwan Jung ; Hyun, Myung Soo ; Kim, Hyo Jung ; Jung, Sin Ho ; Park, Keunchil ; Ahn, Yong Chan ; Ahn, Myung Ju. / Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer : A multicenter randomized phase II trial (KCSG-HN10-02). In: Radiotherapy and Oncology. 2016 ; Vol. 118, No. 2. pp. 244-250.
@article{3e9a5c81179142e19f6c60faf1f3ea49,
title = "Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02)",
abstract = "Purpose Triweekly delivery of cisplatin concurrent with a course of radiation therapy (RT) has been the standard regimen for treatment of locally advanced nasopharyngeal carcinoma (NPC) despite a high level of concern regarding treatment-related complications. We conducted a randomized phase II study to compare weekly and triweekly cisplatin delivery during RT with respect to efficacy and toxicity profiles. Material and methods Patients with locally advanced NPC (stage II-IVb) were randomly assigned to a regimen of either seven doses of cisplatin (40 mg/m2) given once a week or three doses of cisplatin (100 mg/m2) given every 3 weeks concurrently during RT. Results Of 109 eligible patients, 53 were assigned to the weekly regimen and 56 to the triweekly regimen. The two groups were comparable with respect to demographic and clinical characteristics. There were no significant differences in mean RT dose (68.3 Gy vs. 67.3 Gy, p = 0.559) and mean cisplatin dose (248.9 mg/m2 vs. 256.6 mg/m2, p = 0.433) between the two regimens. The primary endpoint was 3-year progression-free survival, which was not different between the regimens (64.9{\%} vs. 63.8{\%}, p = 0.074). Overall, the occurrence of grade 3-4 toxicities was similar between the two arms (47.2{\%} vs. 39.3{\%}, p = 0.443). Quality of life (QoL) related to functional outcomes 3 weeks after treatment completion was better for the weekly regimen. Conclusions Although no definitive conclusions can be made, a once-weekly cisplatin regimen appears to be associated with improved QoL and is not inferior to the standard triweekly regimen with respect to efficacy and toxicity profiles.",
keywords = "Concurrent chemoradiation therapy, Efficacy, Nasopharyngeal cancer, Quality of life, Toxicity",
author = "Lee, {Ji Yun} and Sun, {Jong Mu} and Oh, {Dong Ryul} and Lim, {Sung Hee} and Juna Goo and Lee, {Se Hoon} and Kim, {Sung Bae} and Park, {Keon Uk} and Kim, {Hoon Kyo} and Hong, {Dae Sik} and Kim, {Jun Suk} and Kim, {Seong Geun} and Yi, {Seong Yoon} and Yun, {Hwan Jung} and Hyun, {Myung Soo} and Kim, {Hyo Jung} and Jung, {Sin Ho} and Keunchil Park and Ahn, {Yong Chan} and Ahn, {Myung Ju}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.radonc.2015.11.030",
language = "English",
volume = "118",
pages = "244--250",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer

T2 - A multicenter randomized phase II trial (KCSG-HN10-02)

AU - Lee, Ji Yun

AU - Sun, Jong Mu

AU - Oh, Dong Ryul

AU - Lim, Sung Hee

AU - Goo, Juna

AU - Lee, Se Hoon

AU - Kim, Sung Bae

AU - Park, Keon Uk

AU - Kim, Hoon Kyo

AU - Hong, Dae Sik

AU - Kim, Jun Suk

AU - Kim, Seong Geun

AU - Yi, Seong Yoon

AU - Yun, Hwan Jung

AU - Hyun, Myung Soo

AU - Kim, Hyo Jung

AU - Jung, Sin Ho

AU - Park, Keunchil

AU - Ahn, Yong Chan

AU - Ahn, Myung Ju

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Purpose Triweekly delivery of cisplatin concurrent with a course of radiation therapy (RT) has been the standard regimen for treatment of locally advanced nasopharyngeal carcinoma (NPC) despite a high level of concern regarding treatment-related complications. We conducted a randomized phase II study to compare weekly and triweekly cisplatin delivery during RT with respect to efficacy and toxicity profiles. Material and methods Patients with locally advanced NPC (stage II-IVb) were randomly assigned to a regimen of either seven doses of cisplatin (40 mg/m2) given once a week or three doses of cisplatin (100 mg/m2) given every 3 weeks concurrently during RT. Results Of 109 eligible patients, 53 were assigned to the weekly regimen and 56 to the triweekly regimen. The two groups were comparable with respect to demographic and clinical characteristics. There were no significant differences in mean RT dose (68.3 Gy vs. 67.3 Gy, p = 0.559) and mean cisplatin dose (248.9 mg/m2 vs. 256.6 mg/m2, p = 0.433) between the two regimens. The primary endpoint was 3-year progression-free survival, which was not different between the regimens (64.9% vs. 63.8%, p = 0.074). Overall, the occurrence of grade 3-4 toxicities was similar between the two arms (47.2% vs. 39.3%, p = 0.443). Quality of life (QoL) related to functional outcomes 3 weeks after treatment completion was better for the weekly regimen. Conclusions Although no definitive conclusions can be made, a once-weekly cisplatin regimen appears to be associated with improved QoL and is not inferior to the standard triweekly regimen with respect to efficacy and toxicity profiles.

AB - Purpose Triweekly delivery of cisplatin concurrent with a course of radiation therapy (RT) has been the standard regimen for treatment of locally advanced nasopharyngeal carcinoma (NPC) despite a high level of concern regarding treatment-related complications. We conducted a randomized phase II study to compare weekly and triweekly cisplatin delivery during RT with respect to efficacy and toxicity profiles. Material and methods Patients with locally advanced NPC (stage II-IVb) were randomly assigned to a regimen of either seven doses of cisplatin (40 mg/m2) given once a week or three doses of cisplatin (100 mg/m2) given every 3 weeks concurrently during RT. Results Of 109 eligible patients, 53 were assigned to the weekly regimen and 56 to the triweekly regimen. The two groups were comparable with respect to demographic and clinical characteristics. There were no significant differences in mean RT dose (68.3 Gy vs. 67.3 Gy, p = 0.559) and mean cisplatin dose (248.9 mg/m2 vs. 256.6 mg/m2, p = 0.433) between the two regimens. The primary endpoint was 3-year progression-free survival, which was not different between the regimens (64.9% vs. 63.8%, p = 0.074). Overall, the occurrence of grade 3-4 toxicities was similar between the two arms (47.2% vs. 39.3%, p = 0.443). Quality of life (QoL) related to functional outcomes 3 weeks after treatment completion was better for the weekly regimen. Conclusions Although no definitive conclusions can be made, a once-weekly cisplatin regimen appears to be associated with improved QoL and is not inferior to the standard triweekly regimen with respect to efficacy and toxicity profiles.

KW - Concurrent chemoradiation therapy

KW - Efficacy

KW - Nasopharyngeal cancer

KW - Quality of life

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84960311559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960311559&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2015.11.030

DO - 10.1016/j.radonc.2015.11.030

M3 - Article

C2 - 26705681

AN - SCOPUS:84960311559

VL - 118

SP - 244

EP - 250

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 2

ER -